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ABSTRACT 
Background: Chronic kidney disease (CKD) is common, affecting 10-15% of the population 
worldwide. It is currently recognised by both cardiologists and nephrologists as a strong risk 
factor for cardiovascular events and death. During the last decades it has been shown that 
CKD leads to a state of activated renin angiotensin-aldosterone system and sympathetic 
nervous system, to endothelial dysfunction, chronic vascular inflammation, mineral bone 
disorder, and in late stages also to an acidotic and uremic cell milieu. Together these 
disturbances create an advanced and rapidly progressing vascular disease, leading to vascular 
stiffening and calcification. CKD patients have chronically low levels of activated vitamin D, 
a vitamin now regarded as a hormone involved in a wide range of processes in the body. It 
affects immune cells, leading to a shift towards anti-inflammatory responses, and inhibits the 
production of oxidants. Vitamin D upregulates the expression of eNOS, a crucial enzyme in 
endothelial function, and downregulates the expression of renin. Accordingly vitamin D 
deficiency might affect several of the processes involved in the progressive vascular disease 
seen in CKD. The aim of this PhD project was to investigate the effects of intervention with 
vitamin D on measures and markers of vascular function, inflammation, and upstream 
epigenetic regulation in patients with CKD. 
Methods and results: We performed a randomised placebo-controlled double blind trial 
(RCT) including 36 participants, with non-diabetic CKD stage 3-4. Patients were randomised 
to intervention for 12 weeks with 1 or 2 µg of paricalcitol, an active vitamin D analogue, or 
placebo.  
In paper I, we investigated physiological measures of macro- and microvascular function as 
well as muscle sympathetic nerve activity. We found that treatment with 2 µg of paricalcitol 
attenuated a decline in endothelial function measured by flow mediated vasodilation and 
iontophoresis by acetylcholine, and that both treated groups showed ameliorated measures of 
microcirculation, compared to placebo. 
In paper II, a milliplex assay was performed to assess cytokine expression before and after 
intervention. We found that treatment with both 1 and 2 µg of paricalcitol suppressed levels 
of PDGF and VEGF, cytokines known to be implicated in vascular function and 
atherosclerosis. We also examined microRNAs, by PCR-techniques, and detected a 
downregulation of microRNAs 432, 495 and 576, shown to be involved in atherosclerosis, 
platelet function and inflammation.  
In paper III, concentrations of microparticles (MPs), and their expression of the vascular 
activation and atherosclerotic markers ICAM-1 and VCAM-1 were determined by antibody 
labelling and flow cytometry. We showed that treatment with paricalcitol induced a decline in 
the expression of ICAM-1 on MPs compared to placebo. The results from the combined 
investigation of cell specific MP profiles showed that treatment with 2 µg of paricalcitol 
resulted in sustained levels of endothelial, platelet and leukocyte MPs, in contrast to the other 
two groups where levels declined.   
Paper IV used meta-analysis techniques to assess the overall effect-size post treatment in flow 
mediated vasodilation (FMD) after intervention with any vitamin D compound. Inclusion 
criteria were any stage of chronic kidney disease, and with no restrictions regarding 
underlying diseases. Four articles fulfilled the criteria, comprising 305 participants. The 
overall effect size was in favour of treatment with vitamin D. The results were strongest for 
the study with the youngest population, for treatment with 2 µg of paricalcitol and treatment 
with cholecalciferol. 
Conclusions: In our examined population, vitamin D has positive effects on endothelial 
macro- and microcirculatory functions, suppress levels of atherosclerotic and inflammatory 
markers and maintain the production of microparticles, potentially due to a more normally 
functioning endothelium.  Important questions that remain are whether these findings may 
translate to effects on hard endpoints, in which patient groups, and the optimal timing of 
initiation of treatment. 
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1 INTRODUCTION 
1.1 THE CARDIORENAL SYNDROME 
Cardiovascular disease (CVD) remains the main cause of death worldwide (1, 2). Well 
established risk factors are hyperlipidaemia, smoking, hypertension and diabetes, although in 
the last two decades, chronic kidney disease (CKD) has come forth with similar importance 
(1, 3). CKD including microalbuminuria is also common, affecting 10-13% of the general 
population (1, 2). The comorbidity of CKD and CVD is nowadays recognised in leading 
clinical guidelines for both cardiologists (4, 5) and nephrologists (6) (Table 1).  
Table 1: Risk stratification for future CV disease/death. Based on ESC European Guidelines 
on cardiovascular disease prevention in clinical practices, Piepoli et al-16 (4).  
 
SCORE= a person´s 10 year risk of CV death; BP=blood pressure; CKD=chronic kidney 
disease; DM diabetes mellitus; CVD=cardiovascular disease. 
An eGFR <60 ml/min is known to be associated with cardiovascular death in the general 
population (7), but a recent meta-analysis of almost 2 million subjects showed that the risk of 
myocardial infarction started to increase even at a mild renal dysfunction with an eGFR 
below 90 ml/min (modification of diet in renal disease formula (MDRD)) (8).  
Not only do CKD patients carry a high cardiovascular risk, they also have a worse prognosis 
once they suffer a cardiovascular event (2, 9, 10). This may be due to direct effects caused by 
the declining renal function and associated vascular disease, but it may also in part be due to 
that CKD patients are treated differently. Szummer et al (10) showed a correlation between 
kidney function and the percentage of early revascularization performed in non-ST elevation 
myocardial infarctions (NSTEMI), with less percutaneous coronary interventions (PCI) with 
declining kidney function. Several factors may contribute to fewer interventions in CKD, 
such as difficulties to correctly diagnose NSTEMI in CKD, fear of contrast-induced 
nephrotoxicity, and challenges with correct dosing.  
The connection between heart and kidney disease comprises a wide spectrum of disorders 
often classified as the cardiorenal syndrome (CRS). The CRS is subgrouped into 5 types 
Low	risk Moderate	risk High	risk Very	high	risk
SCORE<1% SCORE		≥1%	and	<5%	 Cholesterol	>8	mmol/L	
(e.g.	in	familial	hypercholesterolaemia)
	
BP	>180/110
DM	(young	people	with	type	1	DM	
without	major	risk	factors	at	low	or	
moderate	risk)
Moderate	CKD	
(GFR	30–59	mL/min/1.73	m2)
SCORE	≥5%	and	<10%	
Documented	CVD
DM	with	target	organ	damage	(e.g.	
proteinuria)	or	major	risk	factor(	e.g.	
smoking,	marked	hypercholesterolaemia,	
marked	hypertension)	
Severe	CKD	(GFR	<30	mL/min/1.73	m2)
SCORE	≥10%	
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based on primary aetiology (2); here the focus will be on the chronic nephrocardiac type 
(Table 2). 
Table 2: Subgroups of the cardiorenal syndrome, based on Ronco et al -08, -14 (2, 11).  
 
AKD= acute kidney disease; DM=diabetes mellitus. 
Several of the mechanisms underlying the chronic nephrocardiac syndrome have been 
investigated during the last decade, outlining a syndrome of advanced vascular disease and 
premature vascular ageing. CKD patients suffer from chronic inflammation, endothelial 
dysfunction, and mineral bone metabolism disorders, leading to vascular calcification and 
arterial stiffening (1, 2, 12, 13). Studies have also demonstrated an activated sympathetic 
nervous system (SNS) and activated renin-angiotensin-aldosterone system (RAAS), 
contributing to the vascular disease (2, 11, 14, 15). In later stages the acidotic and uremic 
milieu in the cells will accelerate the inflammatory process further. All these changes together 
create the perfect conditions for atherosclerosis, vascular stiffening and fibrosis (1, 2, 14, 16, 
17). 
 
1.2 VASCULAR DYSFUNCTION IN CKD 
1.2.1 RAAS and SNS activation 
Both the RAAS and the SNS are highly activated in patients with CKD (2, 11, 14, 15). Renin 
release is stimulated by a decrease in renal perfusion pressure, and by sympathetic nerve 
stimulation (18). Furthermore, low levels of active vitamin D in CKD cause an upregulation 
of renin expression (19), and may contribute to the higher blood pressure seen in CKD, 
although the importance of this mechanism remains controversial (20). The sympathetic over-
activation in CKD is likely due to a combination of renal injury, ischemia, chemoreflex 
dysregulation, and increases in sympathoexcitatory substances (i.e. Angiotensin II) (21). 
Type Classification
1 Acute cardiorenal. Heart failure leading to acute kidney disease
2 Chronic cardiorenal. Chronic heart failure leading to kidney failure
3 Acute nephrocardiac. AKD leading to acute heart failure
(uremic cardiomyopathy, AKD-related)
4
Chronic nephrocardiac. Chronic kidney disease leading to heart disease 
(left ventricular hypertrophy, left ventricular diastolic dysfunction, chronic ischaemic 
heart disease due to kidney disease)
5 Secondary: Systemic disease leading to kidney and heart failure 
(sepsis, vasculitis, DM).
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While these two systems are essential for homeostasis, a chronic activation is deleterious for 
the kidneys, vessels and the heart (14, 22). Sustained RAAS activation causes sodium and 
water retention, systemic vasoconstriction, fibrosis and oxidative stress (14, 22). Sustained 
SNS activation induces reactive oxygen species (ROS) production, reduces β-adrenoreceptor 
density and sensitivity, causes cardiomyocyte hypertrophy and subsequent heart failure, and 
vascular hypertrophy (23-25). 
Angiotensin II, the potent end product of the RAAS system, is an important link between the 
RAAS and the activated immune system seen in CKD. Angiotensin II does not only stimulate 
central sympathetic outflow, but also activates and stimulates monocytes/macrophages, 
dendritic cells, NK-cell and neutrophils as well as proinflammatory T-cells, and induces 
reactive oxygen species (ROS) production chemotaxis and proinflammatory cytokine release 
(26-28). ROS also interplay with SNS, with increased levels by SNS signalling, and at the 
same time enhance SNS activity by promoting sympathetic outflow (23, 29) (Figure 1).  
 
Figure 1: Angiotensin II, the immune system, and the connection to SNS, leading to vascular 
inflammation.  
1.2.2 The immune system 
The immune cells are currently not only regarded as major players in cancer and autoimmune 
diseases, but are also central in the development of atherosclerosis and hypertension (28-31). 
Current research has shown that both the innate and the adaptive immune system are 
implicated in the process (32, 33). Both these immune systems are further dysregulated in 
CKD patients, shown by dysfunctional immune cells, by increased levels of proinflammatory 
RAAS	
Angiotensin	II	
Immune	cell	
Potential	positive	feedback	loop	
Immune	cell	activation	 Production	of	mediators	
Maturation	
Antigen	presentation	
Cell	proliferation	
Cell	differentiation	
Chemokines	
Adhesion	molecules	
Growth	factors	
Cytokines	
ROS	
Chemotaxis	
Adhesion	to	endothelial	cells	
Migration	into	tissues	
Vascular	inflammation	
SNS	activation	
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cytokines and acute phase proteins (34-37). The starting point of this activation in CKD 
patients is not fully understood and probably multifactorial. Hypertensive stimuli and shear 
stress are thought to lead to the formation of neoantigens presented to T helper cells by 
dendritic cells (DCs) thereby activating them (28). An activated RAAS and SNS as described 
above also contribute, and in later stages uremic toxins play an important role as antigens in 
the body and lead to additional activation of the immune system (2, 16). Many cytokines 
produced by immune cells are shown to play an active role in the development of kidney 
injury and disease by enhancing inflammation, fibrosis and proteinuria. Among those are 
platelet derived growth factor (PDGF), vascular endothelial growth factor (VEGF), 
transforming growth factor-β (TGF-β), interleukin-1 (IL)-1, IL-6 and tumour necrosis factor-
α (TNF-α) (37-41). PDGF and VEGF are also thought to play an active role in the 
development of atherosclerosis and atherosclerotic plaques (42, 43). ROS, produced by the 
activated immune cells, are important in the development of endothelial dysfunction, and in 
keeping the feedback-loop mechanisms of inflammation active.  
1.2.3 Endothelial dysfunction  
Micro- and macrovascular endothelial dysfunction is evident from the early stages of 
atherosclerosis, and is a potent independent predictor of cardiovascular risk (17, 31, 44-46). 
Several studies have described endothelial dysfunction in patients with varying degree of 
CKD, and it plays an important role in the chronic nephrocardiac syndrome (17, 47-49). The 
endothelium controls vascular tone, permeability of immune cells and molecules, and 
haemostasis in the blood vessel. Endothelial cells biosynthesize several vasoactive 
substances, and in normal homeostasis keep the balance between vasodilatory, anti-
inflammatory properties, and vasoconstrictive, proinflammatory properties. One of the most 
important vasoactive substances produced by the endothelial cells is nitric oxide (NO). NO is 
essential for a normal endothelial function and inhibits platelet aggregation, transcription of 
cell adhesion molecules, leukocyte adhesion and growth of vascular smooth muscle cells (50, 
51). A central mechanism in the development of endothelial dysfunction is the uncoupling of 
endothelial NO synthase (eNOS). Reactive oxygen and nitrogen species (ROS/RONS) and 
NADPH oxidases are believed to play a major role in uncoupling endothelial nitric oxide 
synthase (eNOS), which turns the enzyme from a protective NO-producing enzyme, to a 
harmful one, leading to production of very potent oxidants (28, 51).  
This loop mechanism created will lead to less NO bioavailability and high levels of 
ROS/RONS. The endothelial cell balance will shift towards a chronic vasoconstrictive, pro-
inflammatory state, with not only activation of endothelial cells, but also activation of 
immune cells. The activated immune cells will produce more pro-inflammatory cytokines 
and ROS/RONS, infiltrate the vessel wall, leading to vascular inflammation and dysfunction, 
and in the end, atherosclerosis (28, 49, 52).  
  5 
1.2.4 Arterial stiffness and calcification 
Arterial calcification and stiffness are important in the development of vascular disease in 
CKD, where impaired vitamin D metabolism, calcium-phosphate imbalance, and 
hyperparatyreoidism play important roles (2). Vascular stiffening is mainly the result of 
endothelial dysfunction, vascular inflammation, and arterial calcification.  
All these processes lead to accelerated vascular disease in CKD, with diminished coronary 
blood flow and risk of myocardial infarction, risk of arrhythmias, of left ventricular 
hypertrophy and sudden cardiac death (1, 2, 49). The causation and interrelationship of these 
different aspects of vascular disease in CKD is however debated (12, 13). Vascular 
inflammation is an early hallmark of vascular disease, and studies have shown that it is 
followed by, but not coexisting with, calcification and fibrosis (13, 53, 54). Calcification and 
fibrosis seem to be due to low-grade long standing inflammation with pronounced structural 
changes (13, 55) and can be seen as the body attempting a healing process, in turn leading to 
arterial stiffening (13). The preceding endothelial dysfunction on the other hand has a strong 
inflammatory connection as described above.  It is activated by inflammation, but also works 
as a promoter of the continuous inflammatory process, and as such is an early sign of the 
vascular disease process (17, 45, 46).  
 
Figure 2: An illustration of some of the complex mechanisms in CKD leading to CVD. The 
many feedback-loops in the network further enhance negative effects (also see Figure 1 and 
text for further details). 
Activated	immune	
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vasoconstriction	Platelet	aggregation	
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1.3 VITAMIN D AS A TREATMENT OPTION 
1.3.1 Vitamin D deficiency and CKD-MBD  
Active vitamin D deficiency is common already from early stages of CKD, mainly due to the 
loss of renal function and availability of 1,25-α-hydroxylase, the vitamin D activating 
enzyme. Low levels of active vitamin D cause insufficient re- and absorption of calcium from 
the kidney and gut, which in turn stimulates release of parathyroid hormone (PTH). High 
levels of PTH stimulate calcium release from skeletal bones, augment absorption of calcium 
from the kidneys, and increase active vitamin D levels (56). Loss of kidney function also 
leads to retention of phosphate, which stimulates both PTH- and fibroblast growth factor 23 
(FGF23) release, the latter a calcium-phosphate regulating hormone, with anti-vitamin D 
properties (57, 58). The changes in this axis in CKD are together known as CKD mineral 
bone disorder (MBD) (59) (Figure 3). There is an ongoing discussion on the importance of 
these different aspects of CKD MBD, but the regulation of FGF23-, phosphate- and vitamin 
D levels are all affected early in CKD patients (59).  
 
Figure 3: The CKD-MBD axis. Ca=calcium; Pi=phosphate; PTH= parathyroid hormone; 
FGF23=fibroblast growth factor 23. 
 
 
Ca↓		Pi↑		
↓GFR	
Phosphate	
retention	
25(OH)D3	
[1α-hydroxylas]	↓		
1,25(OH)2D3	↓		
PTH↑			
[1α-hydroxylas]	↑	
↑Ca2+	absorption	
↑Pi		absorption	
↑Ca2+	reabsorption	
↑Pi		reabsorption	(probably)	
1,25(OH)2D3	↑	
↑Ca2+	re-and	absorption	
↓	Pi		reabsorption		
FGF23↑	
Bone	absorption	↑Ca2+	
[1α-hydroxylas]	↓		
24-hydroxylas↑	
1,25(OH)2D3	↓	
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1.3.2 Vitamin D and CVD 
Several observational studies, including all types of populations, have shown a strong 
association between vitamin D deficiency and an increased risk of cardiovascular events (60-
68). The causality of this association is however still debated. 
Table 3: Examples of epidemiological studies on vitamin D and cardiovascular disease. 
 
CVD=cardiovascular disease; MI=myocardial infarction; DM=diabetes mellitus; 
CHD=coronary heart disease; IHD=ischaemic heart disease. 
Vitamin D treatment is an established treatment of hypocalcaemia and secondary 
hyperparathyreoidism in patients with more advanced kidney failure. However, due to the 
findings in observational studies, the interest for vitamin D as a possible treatment option to 
affect cardiovascular risk in earlier stages of CKD has increased.  
 
1.3.3 Treatment or supplementation? 
There is an ongoing discussion about how to treat CKD patients with vitamin D deficiency. 
Some argue that supplementation with the precursors cholecalciferol or ergocalciferol might 
be preferable over the active hormone calcitriol, or vitamin D receptor analogues (VDRAs, 
i.e paricalcitol). Many cells of the body are now known not only to have the receptor for  
Author Population Participants Outcome
Martins - 07 NHANES 15 088
25(OH)D levels correlate
 to CV risk factors
Wang - 08 Framingham Offspring 1739
25(OH)D deficiency associated 
with incident CVD
Giovannucci - 08
 Health Professionals 
Follow-up Study 18 225
Low levels of 25(OH)D associated with
 higher risk of MI 
Kendrick - 09
Third National Health and Nutrition 
Examination Survey 16 603
Strong and independent relationship
 of 25(OH)D deficiency with prevalent CVD 
Semba -10
Prospective cohort study
 of aging in Tuscany, Italy 1002
 Low serum 25(OH)D levels associated with
 higher risk of all-cause and CVD mortality.
Brondum-
Jacobsen -12
Prospective cohort of
 general Danish population 10 170
Decreasing  25(OH)D levels associated with
risk of IHD, MI, and early death 
Wang -12
Meta-analysis, association of 25(OH) 
vitamin D with CVD risk 65 994
Linear inverse association between 
25(OH)D and risk of CVD 
Brondum-
Jacobsen -12
Meta-analysis, association of 25(OH)D, 
CV risk, MI and early death 82 982
Decreasing  25(OH)D levels associated with
risk of IHD, MI, and early death 
Schottker -13
German population-based 
cohort aged 50–74 9758
25(OH)D inversely associated with all-cause,
 CV, cancer and respiratory mortality 
Heidari -15
Community dwelling type 2 DM
 patients followed to first CHD 2607
25(OH)D deficiency an independent 
predictor of future CHD events
 8 
 
 
active vitamin D (VDR), but also the 1-α-hydroxylase, and are capable of producing active 
vitamin D locally. Studies have indicated potential drawbacks with active treatment, such as 
hypercalcaemia and hyperphosphataemia affecting vascular calcification, induction of 
adynamic  bone disorder and also negative loop back mechanisms with downregulation of 1-
α-hydroxylase and upregulation of  24-hydroxylase, an enzyme that degrades active vitamin 
D (69). Supplementation with the inactive form might give the positive pleiotropic effects of 
VDR-activation through local production of the active form and thereby activation of the 
VDR (69). Precursors seem to safely lower PTH and ameliorate 25OHD and 1,25OH2D3-
levels, in all CKD stages, though at some less degree than active treatment, and without a rise 
in calcium and phosphate levels (70, 71). Active treatment on the other hand is correlated to 
higher calcium and phosphate levels (72-75). In a meta-analysis with both compounds Xu et 
al (75) did not however see a difference in calcium levels between precursors and active 
treatment. Some advocate a combination of supplementation with precursors and active 
treatment (76). 
 
1.3.4 Cellular effects of vitamin D 
On the cellular level, it is now clear that vitamin D not only regulates the bone-mineral 
metabolism, but also displays a wide range of effects in the body. Both the receptor and the 
Vitamin D activating enzyme are found in many different cell types, among them immune 
cells, vascular smooth muscle cells and endothelial cells (77-79). In the immune system, 
vitamin D seems to play a role as a balancing factor between pro- and anti-inflammation (78, 
80). It has both antibacterial and proinflammatory effects by inducing production of 
antimicrobial peptides and bacterial killing by monocytes and macrophages. Vitamin D also 
mediates anti-inflammatory and anti-fibrotic responses by the suppression of 
proinflammatory cytokines, induction of anti-inflammatory cytokines, downregulation of the 
TGF-β pathway and differentiation of T helper (Th) cells towards the less inflammatory Th2 
and anti-inflammatory regulatory T cells (74, 81).  
In the endothelium, Vitamin D has been shown to decrease the expression of adhesion 
molecules, decrease levels of oxidative stress, upregulate the enzyme eNOS and thereby 
induce the production of NO (82-85). Vitamin D is also a negative regulator of the RAAS by 
a downregulation of renin expressing genes (86, 87), and by antagonistic synergy with the 
angiotensin II receptor-1 (AT1-receptor) (88-91). 
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Figure 4: Vitamin D actions in immune cells. From Hewison et al -09 (80). Published with 
permission from Springer Nature. VDR=vitamin D receptor; CYP27b1=1-α-hydroxylase; 
Treg=regulatory T-cell; Th=T helper cell; Ig=immunoglobulin 
 
1.4 INTERVENTIONS WITH VITAMIN D IN CKD 
1.4.1 Studies on markers of inflammation, renal function and glucose 
metabolism  
Three studies between year 2005 and 2010 showed that supplementation with vitamin D and 
treatment with VDRA in patients with CKD was associated with improved survival and 
reduced proteinuria (92-94). Meta-analyses on the topic confirm these results, and show that 
vitamin D affects residual proteinuria in CKD patients, on top of RAAS blockade (72-75). 
The effects are probably due to the anti-inflammatory actions (74) and the effects on the 
RAAS described above (86, 87, 91). Glucose metabolism is another interesting area, where 
one meta-analysis on dialysis patients shows positive effects on glucose control by treatment 
(95). When it comes to inflammatory markers, a couple of small randomised controlled trials 
(RCTs) have shown effects on proinflammatory cytokines and CRP (96-99), while Thethi et 
al (100) failed to show effects on similar parameters. 
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1.4.2 Studies on hard endpoints are lacking  
Large and sufficiently long studies to evaluate hard endpoints are still lacking in this area. In 
a retrospective trial, Lishmanov et al (101) showed reduced cardiovascular events with 
vitamin D supplementation in patients with CKD. Meta-analyses on cardiovascular risk and 
mortality have been performed and show effect of treatment with vitamin D in CKD patients 
in observational studies (102, 103). One meta-analysis (104) investigated the effect on 
cardiovascular endpoints in controlled trials, but could not show any benefit of treatment. 
However, these results may be questioned since none of the included studies had 
cardiovascular endpoints defined à priori, and the study durations varied from only 3 weeks 
to 2 years.  
 
1.4.3 Surrogate markers of CV risk 
In the absence of hard endpoints, many studies have instead used surrogate markers of 
cardiovascular risk, such as flow-mediated vasodilation (FMD) and measures of arterial 
stiffness (pulse wave velocity or pulse wave analysis; PWV/PWA). Whereas PWV/PWA are 
complex measures of arterial structural changes, and are mainly measures of arterial stiffness 
(12, 105), FMD is primarily a measure of the capacity of the endothelial cells to produce and 
respond to NO (106). Still, PWV and FMD are interrelated (107) and both are predictors of 
cardiovascular risk (17, 45, 46, 108, 109). 
 
1.4.4 Studies on FMD 
During the last years a couple of studies have been performed investigating the effects of 
different vitamin D compounds on FMD (44, 100, 110-113). Most of them showed effects of 
supplementation or treatment on measures of FMD in CKD patients in stage 3-4 (44, 111-
113). Kendrick et al (110) compared the effect of supplementation and active treatment, and 
did not detect any difference from baseline for the two groups. Neither did Theti et al (100), 
investigating the effects of paricalcitol in patients with diabetic nephropathy. These studies 
are systematically reviewed in the present thesis in study IV. 
 
1.4.5 Studies on arterial stiffness and diastolic measures 
Left ventricular hypertrophy and diastolic dysfunction is often a result of hypertension and 
arterial stiffness (114-116). Interventional studies with vitamin D on left ventricular mass  
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(LVM), diastolic measures and arterial stiffness have, compared to FMD, primarily shown 
negative results. The PRIMO trial failed to show effects on left ventricular hypertrophy and 
diastolic function in CKD patients (117). However, secondary and explorative analyses 
showed less hospitalizations due to cardiovascular events, and a tendency to positive effects 
on levels of NT-proBNP, and atrial volume indexes. Several studies investigating the effects 
of vitamin D compounds on measures of PWV and/or PWA in kidney disease patients have 
been performed during the last decade (44, 82, 111, 112, 118-123). The study durations 
varied from 8 to 44 weeks, patients were in kidney stage 3-5 and both active treatment and 
supplementation in different doses were used. Levin et al and Kumar et al (111, 112, 119) 
showed positive effects of treatment, whereas the rest of the studies failed to show any 
difference in PWV and/or PWA post treatment.  
 
1.4.6 Other non-invasive methods to assess vascular function 
There are other non-invasive methods to assess vascular and endothelial function, such as 
investigations of skin microvascular reactivity by LDF during iontophoresis with 
acetylcholine (ACh) and sodium nitroprusside (SNP), laser Doppler fluxmetry (LDF), 
reactive hyperaemia index (RHI) and subendocardial viability ratio (SEVR). These are less 
validated as risk markers, but iontophoresis with ACh and SNP have been shown to correlate 
to CV risk factors (124), and might reflect microvascular dysfunction in the rest of the body 
(125). However, Jekell et al (126) showed that iontophoresis by ACh (endothelium 
dependent), LDF and SEVR were not correlated to cardiovascular risk in terms of the 
Systematic COronary Risk Evaluation (SCORE) estimates in a population of hypertensive 
patients. This was in contrast to PWV and FMD that both significantly correlated to SCORE. 
FMD and PWV also correlated significantly to each other, whereas the other measures did 
not, raising important questions about what these measures exactly stand for in the 
vasculature. There are not many studies performed on the effects of vitamin D treatment with 
these measures in CKD patients. Dreyer et al (82) showed positive effects of treatment with 
ergocalciferol on measures of iontophoresis. Pihlström et al, (123) using active treatment, 
could not show any effects of intervention on measures of reactive hyperaemia index (RHI). 
In conclusion, there are still conflicting results in the field of Vitamin D treatment as a way of 
affecting measures of cardiovascular risk in CKD. Factors such as study size and duration, 
study population, and the choice of outcome-measures are of importance to interpret these 
results. 
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Table 4: Interventions with Vitamin D in chronic kidney disease, on surrogate markers of 
cardiovascular risk. For study populations nr in ( ) are patients analysed. 
 
ITT=intention to treat; eGFR=estimated glomerular filtration rate; HD=hemodialysis; 
ESRD=end stage renal disease; FMD=flow mediated vasodilation; PWV/PWA=pulse wave 
velocity/analysis; vWF=von willebrand factor; echo=echocardiography; hsCRP=high 
sensitive CRP; cBP=central blood pressure; LDF=laser Doppler flowmetry: 
eNOS=endothelial nitric oxide synthase; RHI=reactive hyperemia index; LVMI=left 
ventricular mass index. 
1.4.7 Studies on endothelial markers in CKD 
An activated and/or dysfunctional endothelium express activation markers such as 
intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), 
von Willebrand factor (vWF) and endothelial leukocyte adhesion molecule (E-selectin). They 
play an important role in the recruitment and migration of white blood cells and platelets to 
the site of inflammation. E-selectin mediates leukocyte rolling, the first step to slow down the 
flow of the leukocytes at the site of inflammation. ICAM-1 and VCAM-1 then induce 
leukocyte arrest whereas ICAM-1 initiates the crawling and intracellular transmigration of 
leukocytes into the vessel wall (127) (Figure 5).  
Author Duration Sample	size	(nr) CKD	stage Treatment Dose Outcome
Zoccali	(-14) 12w 89	(88) 3-4 paricalcitol 2μg	daily FMD
Chitalia	(-14) 16	weeks 26 3-4 cholecalciferol 300000IU	at	baseline,	
after	8w
FMD,	PWV/PWA,	
ICAM,	VCAM,	E-selectin,	vWF
Theti	(-15) 12w 60	(46) 3-4 paricalcitol 1μg	daily FMD
Kumar	(-17) 16w 120	(117) 3-4 cholecalciferol 300000IU	at	baseline,
	after	8w
FMD,	PWV
Kumar	(-18) 16w 31 3-4 cholecalciferol 300000IU	at	baseline,	
after	8w
FMD,	PWV,	vWF
Kendrick	(-17) 6	months 128	(115) 15-44	eGFR Cholecalciferol,	
calcitriol
2000IU,	
or	0,5μg	daily	
FMD
Marckmann	(-12) 8	weeks 52 HD	comp
	non	HD
cholecalciferol 50000IU/w PWV/PWA,	
vWF,	IL-6,	hsCRP
Hewitt	(-13) 6	months 60 HD cholecalciferol 50000IU/w:	8	w,
	monthly	4m
PWV
Mose	(-14) 6	months 64 ESRD cholecalciferol 3000IU	daily PWV,	PWAix,	
Echo,	cBP
Dreyer	(-14) 6	months 38 3-4 ergocalciferol	 50000IU/w:	1	month,	
montly:	6m
	PWV,	iontophoresis
	LDF,eNOS
Pihlström	(-17) 44w 77 renal	transplant
	recipients
paricalcitol 2μg	daily PWV,	RHI
Levin	(-17) 6	months 119	(87) 15-45	eGFR Calcifediol,	
calcitriol
5000IU		or
0,5	μg	3	times/w	
PWV
Thadhani	(-12) 48w 227 15-60	eGFR paricalcitol 2μg	daily LVMI,	echo
Naeini	(-17) 6	months 64 ESRD vitamin	D	pearls 50000IU/w:3m,
		every	3:rd	w:	3m
VCAM,	ICAM
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Figure 5: The interaction of adhesion molecules and leukocytes (simplified). Modified from 
Ley et al (127). Published with permission from Springer Nature. 
 
These events play an important role in the atherosclerotic process (128) and in line with this 
some studies have shown that levels of ICAM-1 correlate to cardiovascular events and death 
in CKD patients (129-131). VCAM-1 seems to correlate to intima media thickness in HD 
patients (132) and to measures of dyslipidaemia (130, 131). There are two studies performed 
showing lower levels of ICAM-1 and VCAM-1 after intervention with vitamin D, interpreted 
as a less inflammatory and less activated endothelium (44, 133).  
 
1.5 MICROPARTICLES  
Microparticles (MPs) are small cell membrane vesicles (100-1000nm) shedded from the 
parent cells, both during activation of the cell but also increasingly during stress and 
apoptosis. They are released in response to proinflammatory cytokines, acute phase proteins, 
ROS, and uremic toxins (134-136). They can be considered cellular biopsies from the tissues 
they are derived from, and are therefore promising biomarkers for various diseases. 
Microparticles contain mRNA, microRNA, receptors and proteins, and there are emerging 
evidence that they are biologically active, affecting cells around them, playing a role in 
intercellular communication (134-137). Different MPs have been shown to act in the 
production of proinflammatory cytokines, in promoting vascular inflammation and 
coagulation and regulating the production of ROS (135, 137).  
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slow	rolling	
arrest	
Adhesion,	
Strengthening	
Spreading		
Intravascular	
	crawling	
Paracellular		
transmigration	
transcellular		
transmigration	
activation	
Endothelial	cells	 Basement	membrane	
Selectins	 Selectin	
signalling	 Chemokines	
ICAM1	
VCAM1	
ICAM1	 PECAM1	 ICAM1	
PECAM?	
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1.5.1 The importance of subtypes of MPs  
Not only their parent cell type but also the mechanism for their release; apoptosis, cell 
damage or activation, induce different patterns of surface markers, such as CD31, CD62E, 
CD62P, or CD144 (134, 138, 139). For endothelial microparticles (EMPs), it seems that the 
subtypes of EMPs reflect different aspects of endothelial function, and might be used to 
classify the type of endothelial injury occurring (134, 138). In acute coronary syndrome for 
example, there are mainly high levels of apoptotic (CD31+) EMPs (138, 140, 141) probably 
reflecting the acute endothelial cell injury due to ischemia. Jimenez et al (138), showed in an 
in vitro study that when apoptosis was induced in endothelial cells, activation markers on the 
cells and activation induced EMPs remained stable, while apoptotic markers on the cells and 
the production of apoptotic EMPs increased rapidly. Dr Lundström et al has also shown 
interesting results in patients with ischaemic stroke or TIA, where different subtypes of 
platelet microparticles (PMPs) reflect opposite correlations to prognosis in patients with 
ischemic stroke.1 Depending on the cell origin and surface molecules, MPs also seem to 
exhibit opposite effects on apoptosis, inflammation and oxidative stress (134, 139, 142-145) 
(Figure 6). 
 
 
Figure 6: Different actions of microparticles due to their release mechanisms.  
  
                                                
1 Published as part of the thesis ”Platelet function and thrombin generation in ischemic stroke – clinical 
correlates and prognostic importance” 2018, by Annika Lundström, part III: Platelet microvesicles are elevated 
after ischemic stroke or TIA – specific subpopulations have different associations to prognosis 
Apoptosis	
Activation	by	protective	mechanisms	
Stress	induced	activation	
Apoptotic	or	stress	induced	microparticles	 Activation	induced	microparticles	
Oxidative	stress	↑	
Inflammation	↑	
Vascular	calcification	↑	
Coagulation	and	thrombosis	↑		
Apoptosis	↑	
	
Cytoprotection	↑	
Inflammation	↓	
Coagulation	and	thrombosis	↓	
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1.5.2 Endothelial microparticles and correlation to future CV risk 
EMPs are novel biomarkers of endothelial dysfunction and injury (134, 135, 137, 146, 147). 
Levels of CD31-positive-CD41-negative (CD31+ CD41-) and CD144-positive (CD144+) 
EMPs correlate with physiological measurements of vascular function, such as FMD and 
PWV (148-152). The marked endothelial dysfunction in CKD patients is also reflected in 
higher levels of CD144+ and CD31+CD41-EMPs compared to healthy controls (147, 149, 
153, 154). CD144+ or CD31+CD41- EMPs, and also CD62E+ EMPs (155), may play a 
predictive role, and high levels correlate with cardiovascular morbidity and mortality in 
atherosclerosis, kidney failure, pulmonary hypertension and heart failure (146, 148, 155-157) 
(Table 5). 
Table 5: Observational studies on microparticles in chronic kidney disease and 
interventional studies in all populations. 
 
ESRD=end stage renal disease; HD=hemodialysis; CAD=coronary artery disease; 
echo=echocardiography; PAOD=peripheral artery occlusive disease; HUVEC=human 
umbilical vein endothelial cell; CRF=chronic renal failure 
Author Population MPs	measured Outcome
MPs	in	CKD	and	
correlations	to	risk
Amabile	2005	
44	ESRD,	32	
healthy	controls
CD31+CD41-,	
CD144+	EMPs Correlation	to	FMD	in	ESRD	
Boulanger	2007	 34	HD	patients CD144+,		CD31+41-	EMPS	
Correlation	to	measures	
of	shear	stress	in	ESRD.		
Amabile	2012	 81	HD	patients CD31+CD41-	EMPs	.	
Levels	predicted	all	cause	and	
CV	mortality	in	ESRD	after	50	months
Dursun	2009
33	pre-HD,	37	HD,	
18	healty	controls
CD144+,		
CD146	+	EMPs
Higher	levels	in	CKD			than		healthy	
controls.	PWV	correlated	to	CD144
Faure	2006	
45	CKD,	30	HD,	
36	healthy	controls
CD144+,	
CD146+EMPs
Higher	in	CRF	and	HD	
patients	than	in	healthy	controls
Chen	YL	2015	
68	CKD-CAD,	10	CAD,	
10	healty	controls CD31+42b-	EMPs
Higher	in	patients	with	CAD	
than	in	patients	with	CAD	and	CKD.
Trappenburg	2012
27	CKD,	
10	healthy	controls
CD144+	EMPs,	
CD41+,	CD62P+	PMPs
Higher	levels	in	CKD4	
and	HD	compared	to	controls	
Interventions
(all	populations)
Augustine	2014 119	patients	referred	
for	stress	echo	
CD31+41+PMPs,	
CD31+41-EMPs,	
erythrocyte	MPs
Increasing	levels	after	stress	echo
in	patients	with	normal	examination,	
but	did	not	change	in	patients	with	
CVD	or		pathologic	stress	echo
Tehrani	2013		 20	type	1		DM	patients CD144+	EMPs
Levels	tended	to	increase	with	
Atorvastatin	treatment	
Mobarrez	2012	 19	PAOD	patients CD144+	EMPs
Increasing	levels	with	
Atorvastatin	treatment
Jia	2017 HUVEC	cell	line AnnexinV+	MPs
MP	release	and	superoxide	generation
significantly	inhibited	by	1,25(OH)2D3	
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1.5.3 Results from interventional studies 
The production and thereby the levels of MPs also seem to be dependent on the capability of 
the cells to become activated. Augustine et al. (158) reported in a study of CD31+ EMP- and 
PMP-response to dobutamine-stress echocardiography, that patients with signs of coronary 
disease (wall motion abnormalities) on the examination did not react with elevated CD31+ 
EMPs or PMPs, whereas patients with a normal stress-test did. These results seem to indicate 
that a dysfunctional endothelium might be less reactive, not producing more MPs in response 
to stress or other events in the same way as in healthy controls or treated patients. Mobarrez 
et al (159) showed similar results in a study on atorvastatin treatment in patients with 
peripheral artery occlusive disease. Patients treated with atorvastatin produced more EMPs 
than the placebo group. This was interpreted as a sign of a more reactive and healthy 
endothelium since atorvastatin has known endothelium-cell protective effects (160). There 
are to our knowledge no interventional studies performed with vitamin D using MPs as 
outcome. Two in-vitro studies (83, 85) on endothelial cell lines show lower levels of CD31+ 
EMPs after vitamin D treatment indicating a protective effect against apoptosis (Table 5). 
MPs are clearly affected by kidney disease, and some subtypes might be of use not only as 
predictors of risk, but also as markers to understand underlying mechanisms. Whether MPs 
may be used as markers of long-term outcome, is insufficiently studied. 
 
1.6 EPIGENETIC REGULATION, A NEW AND EXPANDING FIELD IN CKD 
1.6.1 Epigenetic regulation 
CKD have a strong hereditary component, shown in epidemiological studies. Genetic wide 
association studies have however failed to find strong associations, implying the importance 
of other factors, such as epigenetic modifications (161, 162). Epigenetic regulation is the 
heritable interface between the rigid genome and the changing environment. It affects gene 
expression without changes in the nucleotide sequence, and therefore epigenetic changes are 
potentially reversible (162). For example, epigenetics are thought to be the reason for the 
interesting phenomenon “metabolic memory”, described in diabetes, where a period of 
impaired glucose control will induce cellular changes that will linger on even after periods of 
excellent treatment (40). 
The most commonly discussed epigenetic regulators are microRNAs (miRs/miRNAs), post-
translational modifications of nucleosomal histones and DNA methylation (Figure 7). 
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Figure 7: The most commonly discussed epigenetic regulations. From Kim et al (163). 
Published in courtesy of the openi agreement:  
https://creativecommons.org/licenses/by-nc-sa/3.0/legalcode 
1.6.2 microRNAs 
miRs are small RNAs (approximately 19-25 nucleotides) that regulate gene expression by 
binding to mRNAs, resulting in silencing of translation or degradation of that mRNA (40). 
These miRs can target hundreds of mRNAs, and their effects on gene expression can 
therefore be substantial (164). Because of this, miRs are not only believed to be future 
biomarkers for various diseases, but also highly interesting as targets for treatment (40).  
Several miRs have been associated with inflammation and kidney dysfunction (40, 162). 
miR-146 and miR-155 are recognized as key players in the immune cell response in chronic 
inflammation (161). miR-192 is well characterized, and promote fibrosis by upregulation of 
profibrotic genes, among them the TGF-β-pathway, known to be central in the development 
of renal fibrosis (162). There are several miRs thought to play a role in normal kidney 
function, among them the miR-30 family (162). As targets for treatment, there are trials 
performed on mice, where an anti-miR192 treatment induced changes in the phenotype of the 
mice with downregulation of mediators of renal fibrosis, and reduced proteinuria (40, 165). 
Several miRs are also thought to be implicated in cardiovascular disease (164). For example, 
downregulation of the miR133 family seems to be implicated in hypertrophy and fibrosis of 
the heart (164, 166). MiR 495 probably acts in the process of platelet reactivity, and 
downregulation of miR495 was shown in a mouse model to ameliorate vascular recovery 
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after ischemia (167, 168). However, here there are conflicting results, where another mouse 
model has shown that miR495 was downregulated in ischaemic tissue, and showed anti-
inflammatory properties (169). An upregulation of a cluster of miRs, among them miR432, 
seems to be implicated in the atherosclerotic process (170). Upregulation of miR 432, as well 
as miR 576, also seems to be implicated in the proinflammatory response, a possible pathway 
of enhancing vascular dysfunction (171, 172). 
Epigenetic regulation plays an active role in kidney disease and cardiovascular disease, as in 
most other diseases, and might be of importance both as predictors of risk, and as possible 
targets for treatment. For the potential role of epigenetic regulation in interventions there is 
still very limited knowledge due to the lack of studies in the field. 
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2 AIMS OF THE THESIS 
The overall aim of this thesis was to reach a higher understanding of cardiovascular disease 
mechanisms and treatment options in chronic kidney disease patients, with focus on the role 
of vitamin D on different aspects of vascular dysfunction.  
The specific aims of the four studies are as follows: 
Study I: To investigate if paricalcitol treatment affects measures of muscle sympathetic nerve 
activity, as well as measures of macro- and microvascular function in moderate CKD. 
Study II: To analyse the effect of paricalcitol treatment on the proinflammatory profile and 
epigenetic modulators, measured by microRNAs, in moderate CKD. 
Study III: To assess the effect of paricalcitol treatment on microparticle expression of ICAM-
1, and VCAM-1, as well as the effect on the profile of endothelial, platelet and leukocyte 
microparticles in moderate CKD. 
Study IV: To investigate, using overall effect size in a meta-analysis, if there is evidence in 
existing publications of an effect of vitamin D treatment or supplementation on endothelial 
function measured by flow-mediated vasodilation. 
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3 MATERIALS AND METHODS 
3.1 STUDY POPULATIONS AND STUDY DESIGN 
3.1.1 The SOLID trial; Study I, II and III 
Patients (n=36) in study I, II and III were recruited from the Department of Nephrology at 
Danderyd University Hospital, Stockholm, Sweden, from 2010 to 2013. They were 
randomised in a double blind manner (12 in each group) to receive 1 µg paricalcitol, 2 µg 
paricalcitol or placebo. Due to the influence of sun, patients were not recruited during 
summer. Inclusion criteria were an estimated glomerular filtration rate (eGFR) of 15–59 
ml/min/1.73 m2 calculated from plasma creatinine using the MDRD formula, age >20 years, 
a plasma PTH level of 3.7–53 pmol/L, a Ca level <2.6 mmol/l, serum albumin >30 g/L and 
being on stable antihypertensive medication with no change in angiotensin converting 
enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB) medication during 2 months 
before enrolling in the trial. Exclusion criteria were nephrotic syndrome, diabetes mellitus or 
any treatment with vitamin D or its analogues that could not be discontinued, acute renal 
failure during the last 3 months, and if expected to need dialysis within 6 months. Patients 
were also excluded if they had known renal artery stenosis, severe kidney stones, 
uncontrolled hypertension (repeated measures of a brachial blood pressure >150/100 mm Hg) 
or other severe disease (active cancer, AIDS/HIV, severe congestive heart failure).  
The study protocol was approved by the regional Ethics Committee in Stockholm, and 
registered on clinicaltrials.gov (SOLID study; NCT01204528). All patients provided written 
informed consent. 
 
Figure 8: Flow chart of the SOLID trial. echo=echocardiography. 
3.1.2 Study IV  
Study IV was a meta-analysis investigating the effect of vitamin D on FMD. Inclusion 
criteria were chronic kidney disease in any stage and with any underlying cause, intervention 
with any vitamin D compound, a study design with a placebo or non-treatment control group, 
and outcome in form of flow mediated vasodilation. Exclusion criteria were combination 
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treatments with vitamin D and calcium, or comparison to other vitamin D compound or 
calcimimetics, without a non-treatment control group. 
 
3.2 STUDY METHODS 
Study I, II, and III started with two weeks of placebo run in, followed by 12 weeks of 
treatment with 1 or 2 µg paricalcitol, or placebo. Venous blood samples were drawn in the 
morning, after 12 h fasting and 20 min rest, at baseline and post treatment. 
3.2.1 Study I 
3.2.1.1 Arterial Stiffness  
To assess arterial stiffness we used applanation-tonometry (SphygmoCor, AtCor Pty, NSW, 
Australia). The equipment was used to acquire a peripheral waveform from which pulse wave 
velocity (PWV) was measured and pulse wave augmentation index (AIx) was calculated. 
(105). To determine PWV, two waveforms were sequentially recorded (carotid- radial artery 
and carotid-femoral artery). The R-wave of a simultaneously recorded ECG was used as a 
reference frame, and the transit time of the pulse wave was then determined. The distance 
was measured and the PWV was determined. To determine AIx, a central waveform was 
assessed by the software, and the augmentation between the first and second systolic pressure 
peak of the wave-form was calculated. The augmentation was then expressed as a percentage 
of the total pulse pressure. 
3.2.1.2 Large Vessel Endothelial Function  
Macrovascular endothelial function was assessed by FMD (106). The brachial artery diameter 
was measured by a vascular ultrasound device with a 9-MHz linear transducer (Vivid 7 
Dimension, GE Medical system, Horten, Norway). Endothelial dependent vasodilation was 
investigated by inducing ischemic reactive hyperaemia with a pneumatic tourniquet inflated 
to 250 mm Hg for 5 min. When released, vasodilation was measured as the relative change 
from rest in brachial artery diameter at 30, 60 and 90s. After 10 min of rest, endothelial 
independent vasodilation was assessed by the administration of 0.4 mg of sublingual glycerol 
trinitrate. The relative change from rest in brachial artery diameter was calculated from 
measurements in diameter 4 min after administration.   
3.2.1.3 Skin Microvascular Function – Perfusion Imaging  
Skin microvascular function was investigated by laser Doppler perfusion imaging before, 
during and after iontophoresis with acetylcholine (ACh; Sigma-Aldrich AB, Stockholm, 
Sweden) and sodium nitroprusside (SNP; Hospira, Inc., Lake For- est, Ill., USA) (173).  ACh 
and SNP, diluted in deionized water, were used to examine endothelium dependent and 
independent skin microvascular function, respectively. Iontophoresis is a non-invasive 
technique using a small electric current for drug administration across the skin. Electrode 
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chambers (LI611 Drug Delivery Electrode Imaging, Perimed, Järfälla, Sweden) were 
attached to the volar side of the left forearm and filled with either ACh (2%) or SNP (2%). A 
battery-powered iontophoresis controller (Perilont 382b, Perimed, Järfälla, Sweden) provided 
a direct current (0.1 mA for 60 s) for drug iontophoresis. ACh was delivered with an anodal 
and SNP with a cathodal charge. Skin microcirculation was measured by laser Doppler 
perfusion imaging (Periscan PIM II, Perimed, Järfälla, Sweden) and expressed in arbitrary 
units (AU). Skin microcirculation was recorded continuously for 10 and 14 minutes after 
iontophoresis of ACh and SNP, respectively. Peak microvascular flux was determined. At our 
laboratory, the mean coefficient of variation of peak microvascular flux after iontophoresis of 
ACh and SNP were 11 and 20%, respectively. 
3.2.1.4 Capillary Blood Cell velocity  
Blood cell velocity in single nailfold capillaries of the great toe was measured during 
videophotometric capillaroscopy (174). Capillary blood cell velocity (CBV) was determined 
by two videophotometric windows positioned along the arterial side of the capillary axis 
detecting variations in optical density when blood cells and plasma gaps are passing through 
the capillary. The variations in light intensity are then converted into an electronic signal. 
Given the distance between the windows and the time delay between similar events in the 
upstream and downstream windows, CBV can be continuously recorded. CBV was measured 
during resting condition and during post-occlusive reactive hyperaemia, performed by a small 
pressure cuff at the proximal phalanx of the great toe. The cuff was inflated to a pressure of 
200 mm Hg for 1 min, and peak CBV (mm/s), time to peak CBV (s), as well as relative 
change from rest (%) were measured. The temperature was continuously recorded during the 
measurements of CBV We have a good reproducibility in our laboratory (175). 
3.2.1.5 Sympathetic Activation  
Muscle sympathetic nerve activity (MSNA) was recorded using microneurography by a 
tungsten microelectrode inserted percutaneously into a muscle fascicle of the peroneal nerve 
(176). The signal was digitized (Powerlab Neuroamp, ADInstruments, Bella Vista, Australia) 
and pulse-synchronised bursts were analysed by a blinded investigator. Heart rate was 
recorded by a standard electrocardiogram, and blood pressure was measured with an 
automatic cuff. MSNA was quantified as bursts per minute (SNA/min) and as bursts per 100 
RR intervals (SNA/RRI).  
 
3.2.2 Study II 
3.2.2.1 Characterization of the expression of immune modulators in plasma 
Using the Luminex technique, a Milliplex 26-plex (Millipore corp.) was performed to assess 
the expression of a wide spectrum of cytokines before and after 12 weeks of paricalcitol 
treatment or placebo. In the Luminex technique, the company prepares microspheres, or 
beads, numbered to allow differentiation, and then covered in different antigen-specific  
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antibodies. They are then put together in different patterns allowing a multiple of molecules 
to be identified in one well simultaneously. The test-sample was then added by us and the 
expression was quantified by labelled detection antibodies (Figure 9).  
 
Figure 9: The LuminexR technique. Published with permission from LuminexR and 
ThermoFisher Scientific.  
 
3.2.2.2 Reverse transcription polymerase chain reaction (RT-qPCR) to assess miRNA 
expression 
We used miRCURY Ready-to-Use PCR Human panel I + II V1.M (EXIQON miRNA qPCR 
panel) (Figure 10) to assess the possible changes in miRNA expression in plasma. It was a 
ready to use kit involving a human miRNA panel, with a first step of reverse transcription 
(RT), of miRNA to DNA, followed by real-time PCR amplification with miRNA specific 
primers. For the first step, Universal cDNA synthesis kit II (miRCURY LNATM Universal 
RT microRNA PCR, EXIQON) was used. We then applied miRNA specific primers and 
ExiLENT SYBR Green master mix kit (miRCURY LNATM Universal RT microRNA PCR, 
EXIQON) for RT-qPCR. Quality control of the RNA isolation was performed by RNA spike-
in (UniSp2, UniSp4, UniSp5), and cDNA synthesis control was assessed by UniSp6 in the 
RT-reaction. In addition DNA spike in (UniSp3) was added in all samples. 
PCR reaction was assessed by MicroAmpTM optical 384-well reaction plates with an ABI 
7900 (Life Technology). As the amount of RNA in a sample is too small for exact 
determination of concentrations, the biofluid input amount in the PCR reaction was used as 
recommended by the manufacturer. 
  
Antigen-specific	capture	antibodies		
are	bound	to	microspheres	
Antigen	from	the	test	sample	is		
bound	to	the	capture	antibodies		
	
Signal	is	generated	by	the	attachment	
of	the	labeled	detection	antibodies		
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Figure 10: The miRCURY-technique. First step is the synthesis of cDNA (reverse 
transcription (RT)) from existing miRNA in the sample. Next steps are amplifications of the 
cDNA produced in the first step by real-time PCR, using miRNA specific primers, and 
quantification of the process with help of SYBR-green. Modified from the miRCURY 
handbook (177). Published with permission from QIAGEN (formerly EXIQON).  
3.2.3 Study III  
3.2.3.1 Assessment of microparticle concentrations 
As previously described (178), plasma was centrifuged at 2,000 G for 20 min to attain platelet 
poor plasma, which was then frozen in aliquots at -80 °C until analysis. Platelet poor plasma 
was thawed and again centrifuged at 2,000 G for 20 min. The supernatant was subsequently 
centrifuged at 13,000 G for 2 min. 20 µL of the supernatant was incubated in the dark with 
lactadherin-FITC (BLAC-FITC, Coatech AB, Klädesholmen, Sweden) which binds to 
phosphatidylserine (PS), together with CD62E-APC (Thermo Fisher Scientific, Waltham, 
MA, USA), CD41-APC (Beckman Coulter, Brea, CA, USA), CD62P-PE (Thermo Fisher 
Scientific, Waltham, MA, USA), CD154-APC (Thermo Fisher Scientific, Waltham, MA, 
USA) CD45-APC (Beckman Coulter, Brea, CA, USA), CD106-PE (VCAM-1, Abcam, 
Cambridge, UK) and CD54-PE (ICAM-1, Abcam Cambridge, UK). MPs were defined as 
particles less than 0.9 µm in size, positive to lactadherin. All samples were analysed using a 
Beckman Coulter Gallios flow cytometer (Beckman Coulter, Brea, CA, USA), and the MP-
gate was calibrated using Megamix beads (FSC; 0.5 µm, 0.9 µm and 3.0 µm, BioCytex, 
Marseille, FR).  
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3.2.4 Study IV 
A systematic literature search of PubMed/Medline, Web of Science (WoS), Embase and 
Cochrane trials and reviews was performed. Search results were restricted to controlled trials 
and to the English language. We used the MeSH-terms for vitamin D as well as kidney 
disease, and all terms listed beneath. The selected articles were coded with a prespecified 
extraction form including study length, number of participants, vitamin D compound and 
dosage, age, CKD stage, other treatments and baseline laboratory measurements such as 
vitamin D status.  Methodological study quality and risk of bias were assessed by the Jadad 
Score, which gives 1-5 points for blinding, randomization and risk of incomplete outcome 
data (the account of all screened and included patients) (179). Selective outcome reporting 
was also assessed during the screening and selection process. To assess publication bias, rank 
correlation and a funnel plot were both performed. We also searched ClinicalTrials.Gov for 
unpublished articles matching our inclusion criteria. 
 
3.3 STATISTICAL ANALYSES 
The SOLID study was a novel hypothesis-testing study, where the study-size was based on a 
treatment-induced change in MSNA. The intention was to study first non-diabetic CKD, and 
then diabetic CKD. Whether vitamin D affected MSNA was unknown, and an estimated 
moderate-large effect size (f=0.36) showed that we needed 36 patients in each group (non-
diabetic and diabetic CKD). We included a pre-specified interim analysis after the first group 
of patients (non-diabetic CKD; n=36). At that interim analysis, we found no significant 
change in MSNA. Instead of pursuing the hypothesis that MSNA might be affected in 
diabetic CKD, due to limited resources, we instead decided to turn to secondary explorative 
outcome measures.  
Descriptive statistics were presented as means and proportions. Between group differences in 
means at baseline were examined by one-way analysis of variance (ANOVA), by the Chi2-
test, or the Fischer´s exact test when appropriate.  
In paper I, the effects of intervention (paricalcitol) and time were investigated for vascular 
function and MSNA by using repeated measures two-way ANOVA as well as by multilevel 
modelling/mixed model (MLM) to improve the statistical power. We also examined the 
effects of intervention and time within groups, by paired t-test. 
In paper II, non-parametric tests were used, as data was non normally distributed. Using the 
same patients, changes in cytokine expression was investigated by Kruskal Wallis (pre- and 
post-measurements separated), followed by Wilcoxon matched-pairs signed rank test for 
within group comparisons over time and Mann Whitney U-test for two independent group 
comparisons. For miRNA, the delta change (post - pre measurements) as well as fold change 
(post/pre measurements) were determined and the between-groups comparison was then 
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performed by non-parametric Kruskal Wallis and Mann Whitney U-test for two independent 
group comparisons.  
In paper III, changes in microparticle-levels and their expressions in the SOLID patients, was 
tested using two-way repeated measures ANOVA (ICAM-1, VCAM-1) and, for the profile of 
subclasses of MPs, two-way repeated measures MANOVA. Post hoc analyses were 
performed with one-way repeated measures MANOVA (main effect of time) and paired t-test 
for within group changes. 
Paper IV, a meta-analysis of treatment with vitamin D to CKD patients, was analysed as post 
treatment comparisons, calculating standardized mean difference effect size (STANDmean 
ES). Weighted standard deviation and then Hedges g were used to calculate effect sizes 
(STANDmean ES) for each study (180, 181). A positive value indicated an effect in favour of 
treatment. The overall effect size was then assessed by a fixed effects model (180). A random 
effects model was also performed as a secondary analysis. I2 statistics were performed to 
assess heterogeneity.  
Statistical analyses were performed using SPSS software, version 22 and 24 (SPSS Inc., 
Chicago, IL, USA) and SAS (version 9.3, SAS Institute Inc., 2002–2010). 
 
3.4 ETHICAL CONSIDERATIONS 
The SOLID trial was performed in accordance with the declarations of Helsinki. All patients 
provided and signed written informed consent. The study was registered at ClinicalTrial.Gov 
as SOLID study; NCT01204528. 
The meta-analysis was performed in accordance with the PRIMA guidelines and MOOSE 
checklist. All included studies assured the use of the declarations of Helsinki and of written 
informed consent. 
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4 RESULTS 
4.1 THE SOLID STUDY; PAPER I, II AND III 
4.1.1 Patient characteristics  
Thirty-six patients were included, and 35 completed the trial. The one person who did not 
complete the trial was in the placebo group, and experienced feelings of dizziness from the 
study drug (placebo) and did not perform the post-treatment measurements. No major adverse 
events were found during the study period, and there were no hospitalizations. Baseline 
characteristics showed that those in the placebo group were slightly older with more previous 
cardiovascular disease, and a tendency to higher number of patients with polycystic kidney 
disease as aetiology of CKD.  
Table 6: Baseline characteristics in the SOLID trial as mean and (SD) or nr and (%). 
 
BMI=body mass index; CKD=chronic kidney disease; TIA= transient ischaemic attack; 
ACE-i=angiotensin converting enzyme inhibitor; ARB=angiotensin receptor blocker; Ca-
flow-inh=calcium-flow inhibitors. Reprinted in courtesy of American Journal of 
Nephrology:2015, 42(4):265-73, by permission of S. Karger AG. 
Characteristics Placebo	(n=12) Paricalcitol	1μg	(n=12)
Paricalcitol	2	μg	
(n=12)
Age	(years) 70.8	(10.0) 66.1	(7.9) 59.1	(11.6)
Sex	(%	male) 9	(75%) 11	(92%) 8	(67%)
Smokers	(current) 1	(8%) 1	(8%) 0
BMI 28.1	(2.4) 26.4	(3.5) 26.8	(2.8)
CKD	duration	(years) 10.3	(8.8) 5.8	(6.0) 9.7	(10.5)
Cause	of	CKD
			Hypertension 3	(25%) 4	(33%) 4	(33%)
			Polycystic	disease 4	(33%) 2	(17%) 1	(8%)
			Glomerulonephritis 4	(33%) 3	(25%) 4	(33%)
			Other	cause 0 2	(17%) 2	(17%)
CVD	at	inclusion
			Myocardial	infarction 3	(25%) 2	(17%) 0
			Atrial	Fibrillation 1	(8%) 1	(8%) 0
			Stroke 3	(25%) 0 0
			TIA 1	(8%) 0 0
			Heart	failure 0 0 1	(8%)
			Aortic	aneurysm 0 1	(8%) 1	(8%)
Medication
			ACE-i/ARB 11	(92%) 9	(75%) 9	(75%)
			β-blockers 6	(50%) 8	(67%) 4	(33%)
			Ca	flow-inh 10	(83%) 8	(67%) 4	(33%)
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The three groups did not differ in eGFR, duration of CKD or serum creatinine levels. They 
were also well matched in routine biochemistry status, measures of vascular function (FMD 
and PWV), microcirculatory function except peak CBV (iontophoresis and videophotometric 
capillaroscopy), and measures of sympathetic nerve activity (MSNA). Measures of cytokine 
expression and concentrations of microparticles were also well matched between groups at 
baseline (Table 6). 
 
4.1.2 Routine laboratory findings post treatment 
There were no significant changes in albumin, UACR or CRP-levels post treatment. Neither 
were there any significant changes in phosphate, 25OH-vitamin D, or calcium. However, 
calcium did change slightly in absolute numbers with highest levels post treatment in the 2 µg 
treatment group. PTH was significantly suppressed by treatment (two-way ANOVA p=0,02 
for treated groups combined, p=0,006 for 3 groups comparison) in a dose dependent manner. 
 
4.2 VASCULAR MEASUREMENTS; PAPER I  
There was a significant decrease in FMD across all groups after 3 months study (MLM main 
effect of time p=0.006). However, when within group changes were examined, the 2 µg 
treated group showed preserved endothelial function (paired t-test p=0.54) (Figure 11a). 
For iontophoresis by acetylcholine the results were similar, with a borderline significant 
decrease across all groups, (repeated measures ANOVA, main effect of time p=0.06) but 
preserved function with no significant decrease for the 2 µg treated group (paired t-test, 
p=0.65) (Figure 11b).  
We also performed videophotometric capillaroscopy. There were however several patients 
where this measure could not be performed. The treated groups were collapsed into one and 
MLM performed on 26 patients. The results showed borderline significant interaction, with 
ameliorated microcirculatory function in the treated groups, and declining function in the 
placebo group, measured as peak CBV (MLM p=0.06). Within group changes also showed 
ameliorated function for the treated group with borderline significance (paired t-test p=0.05) 
(Figure 11c). 
  31 
Figure 11: Measures of FMD, iontophoresis by acetylcholine and peak capillary blood cell 
velocity pre- and post treatment. Reprinted in courtesy of American Journal of 
Nephrology:2015, 42(4):265-73, by permission of S. Karger AG. 
We did not detect any change by intervention and time in PWV, PWAix or MSNA. For 
MSNA there was only complete data for 24 patients, but with MLM, 11 of those with 
incomplete data could contribute with values in the analysis. 
 
4.3 PROINFLAMMATORY CYTOKINES AND miRNAs; PAPER II 
When comparing pre- and post-measurements of a range of proinflammatory cytokines, 
VEGF and PDGF were significantly decreased in the two treated groups, but remained 
unchanged in the placebo group (Wilcoxon matched pairs for within group changes). Levels 
of interferon gamma induced protein 10 (IP10), a cytokine central in the enhancement of the 
inflammatory response, were also decreased for treated patients, but only significantly for the 
2µg treated group (Wilcoxon matched pairs) (Table 7).  
Figure 11a 
Figure 11c 
Figure 11b 
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Table 7: Concentrations of cytokines (pg/ml) pre- and post intervention, including p-values. 
Reprinted in courtesy of BMC Nephrology: 2017, 18(161), in line with the open access 
agreement for Springer Nature. 
The two treatment groups were also collapsed into one, to obtain better power, and we then 
detected a significant decrease in a wide range of cytokines (Wilcoxon matched pairs), in 
comparison with placebo where there were no significant changes during the study (Figure 
12). 
 
Figure 12: Changes in cytokine levels pre-post treatment in the collapsed treatment groups. 
P-values indicated in the figures. There were no significant changes in the placebo group. 
To determine possible changes in miRNAs post treatment, we first performed a pilot study of 
five randomly selected patients on 2 µg paricalcitol treatment. The top five (p-value and fold 
change) changed miRNAs were miR 133a, miR432, miR 495, miR 576 and miR 874. These 
were then analysed in all 36 patients. We chose to include also the five patients in the pilot 
study in the final analysis to obtain better statistical power. MiR 432, miR 495 and miR 576 
were all significantly downregulated by 2µg of paricalcitol treatment (Kruskal-Wallis and 
post hoc Mann-Whitney U-test comparisons of delta value and fold change) (Figure 13). The 
effect was similar when collapsing the treatment groups.  
                   Placebo             Paricalcitol 1µg               Paricalcitol 2µg
         Pre                     Post        Pre                        Post        Pre                            Post
VEGF     20 (9-36)            18 (13-21) 0.2    20 (15-31)           10 (3-15) 0.01     26 (9-60)                 10 (7-32) 0.02
PDGF 1220 (719-3740)    837 (411-3084) 0.2 1297 (960-1933)   784 (561-915) 0.005  2811 (1447-3706)   1234 (1003-2239) 0.009
IP-10 342 (169-5167)      332 (71-5091) 0.8  423 (353-2805)    402 (274-614) 0.08 2628 (511- 6200)     492.5 (270-2022) 0.02
Cytokine p-value p-value p-value
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Figure 13: The five top ranked miRNAs validated in all patients, as fold change (post/pre 
measurements). Significant change by treatment indicated with p-value. Reprinted in courtesy 
of BMC Nephrology: 2017, 18(161), in line with the open access agreement for Springer 
Nature. 
 
4.4 ENDOTHELIAL MICROPARTICLES AND VASCULAR BIOMARKERS; 
PAPER III 
In this study, we investigated the change in expression of ICAM-1 and VCAM-1 on 
microparticles as well as the change in total MP profile during intervention. 
There was a change by treatment in the expression of ICAM-1 on MPs, seen by a significant 
interaction (repeated measures two-way ANOVA p=0.04), with augmented levels in the 
placebo group, and decreased levels in the treated groups (Figure 14a). This was not seen for 
the expression of VCAM-1 on MPs, where the levels remained stable during intervention 
(repeated measures two-way ANOVA p=0.52). 
To avoid multiple comparisons, a two-way repeated measures MANOVA was used, to 
investigate the changes in cell-specific MP subtypes (CD62E+ EMPs, CD41+ PMPs, CD41+ 
CD62P+ PMPs, CD41+CD154+ PMPs and CD45+ LMPs). There was a significant decrease in 
all MP subtypes during the study (repeated measures MANOVA, main effect of time 
p=0.001), with a tendency to interaction between treatment and time (repeated measures two-
way MANOVA p=0.08). Post hoc analyses with one way repeated measures MANOVA 
showed that the findings were due to sustained levels in the 2 µg (p=0.85), and significantly 
decreasing levels in the 1 µg (p=0.04), and placebo group (p=0.005) Figure 14b).  
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Fig 1. Significantly changed plasma microRNAs following treatment, comparing the three groups;
placebo, 1 µg and 2 µg. Scatter plots represent 25-75 % interquartile range with a line at the median.
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Focusing on EMPs, further analyses demonstrated that EMP levels were not significantly 
changed for either the 1 or 2 µg treatment groups during the study (1 µg, paired t-test, p=0.10, 
and 2 µg, p=0.3), while decreasing in the placebo group (paired t-test, p=0.002). In absolute 
numbers, a pattern of dose dependent change was observed (Figure 14c). 
 
 
Figure 14: Pre and post measurements of microparticles. MP=microparticle; 
CD62E+MPs=EMPs 
  
Figure	14a	
Figure	14b	 Figure	14c	
	Treatment	
	placebo	
	1	μg	
	2	μg	
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4.5 OVERALL EFFECT SIZE BY PARICALCITOL TREATMENT ON FMD; 
PAPER IV 
4.5.1 Study selection and population 
In total, 1.744 articles were found searching the databases. After screening of title and 
abstract 304 articles remained, and 14 were selected for full review. Of these, four studies met 
the full inclusion criteria (Figure 15). However, one of the studies comprised two treatment 
groups (1 and 2 µg of paricalcitol; study one in the present thesis) and after discussion, this 
study was split in two, using the same placebo group as control, thus resulting in five studies 
in the final analysis.  
 
 
Figure 15: Flow chart of the selection process. WoS=Web of Science; Reprinted in courtesy 
of BMC Nephrology: 2018, 19(247), in line with the open access agreement for Springer 
Nature. 
 
All included patients were in CKD stage 3-4. Mean age was 59.9 years, ranging from 44-65 
years. Study size varied from 24-120 participants, and study duration from 12 to 16 weeks. 
One study investigated the effect of cholecalciferol in two oral doses of 300 000 IU at 
baseline and after 8 weeks, while the others used paricalcitol 1 or 2 μg daily (Table 8). 
  
Results	from	systematic	search:	
Pubmed:	299	
Cochrane:	300	
WoS:387	
Embase:	758	
Total:		1744	
Articles	remaining	:	304	
Articles	remaining	for	full	text	revision	:	14	
Full	text	articles	included	in	meta	
	analysis:	4		
	Review	or	meta	analysis		
	No	intervention	
	Outcome	other	than	vascular	
	Combination	therapy	with	Calcium	
	Nr:	290	
	Duplicates	by	databases:	34	
	Duplicate	publications:2	
	Not	CKD	
	Not	investigating	vitamin	D	
	Pediatric	population	
	Animal	studies	
	Nr:	1385	
	Vascular	outcome	other	than	FMD:	8	
	No	placebo	group:	2	
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Table 8: Baseline characteristics of the included studies in the meta-analysis. 
 
ACEi=angiotensin converting enzyme inhibitor; ARB=angiotensin receptor blocker; 
DM=diabetes mellitus; ITT=intention to treat; FMD=flow mediated vasodilation; 
PWV=pulse wave velocity; echo=echocardiography. Reprinted in courtesy of BMC 
Nephrology: 2018, 19(247), in line with the open access agreement for Springer Nature. 
4.5.2 Study quality and bias 
Both the Jadad score and the Cochrane handbook 5.1 were used to evaluate study quality and 
risk of biased data. Included studies had Jadad scores from 3 to 5, indicating median to high 
quality. There were no signs of selective outcome reporting when performing the literature 
screening and selection. Overall, this indicated a low risk of biased data. Rank correlations 
and visual inspection of a funnel plot did not indicate publication bias. This conclusion was 
also strengthened by the search in ClinicalTrials.Gov, where there were no unpublished trials 
of interest to our inclusion criteria. 
4.5.3 FMD outcome 
The five included studies comprised 305 patients. Patients were well matched in terms of 
FMD at baseline in each study. The fixed effects model analysis showed a positive effect of 
vitamin D treatment on FMD (STANDmean ES 0.78, 95% CI 0.55-1.01) (Figure 16). A 
random effects model performed as a secondary analysis also showed significantly positive 
effects of treatment (STANDmean ES 0.67 95% CI 0.06-1.29). The heterogeneity was 
substantial for the fixed effects model (I2=84 %), but minimal for the random effects model 
(I2=0 %). There were too few studies included to perform a meta-regression to statistically 
investigate the heterogeneity in the fixed model. 
Author Zoccali	(-14) Lundwall	2μg	(-15) Lundwall	1μg	(-15) Theti	(-15) Kumar	(-17)
Country Italy Sweden Sweden USA India
Duration 12w 12w 12w 12w 16w
Sample	size	(nr) 89,	analysis		on	88 24,	ITT 24,	ITT 60,	55	completed,	
analysis	on	46
120,	analysis	on	117
CKD	stage 3-4 3-4 3-4 3-4 3-4
Treatment paricalcitol paricalcitol paricalcitol paricalcitol cholecalciferol
Dose 2μg	daily 2μg	daily 1μg	daily 1μg	daily 300000IU	at	baseline
	and	after	8	week
Baseline	25(OH)D		(nmol/l) 35.5 65.1 66.7 1.25-OHD:	34.5	(pg/ml) 33.2
Age		(mean) 62.5 65.0 68.5 62.5	(median) 44.2
ACEi/ARB	(%) N/A 80.6 80.6 69.1 67.5
Jadad	score	 4 4 4 3 5
Underlying		condition/DM N/A Non-diabetic	patients Non-diabetic	patients Diabetic	nephropathy Non-diabetic	patients
Outcome FMD FMD,	PWV,	echo,	
iontophoresis,	microcirc
FMD,	PWV,	echo,
	iontophoresis,	microcirc
FMD FMD,	PWV
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Figure 16: Forest plot of effect sizes in the included studies. Overall effect size in a fixed 
effects model. Reprinted in courtesy of BMC Nephrology: 2018, 19(247), in line with the 
open access agreement for Springer Nature.
-1	 -0.5	 0	 0.5	 1	 1.5	 2	
Zoccali	et	al	-14	
Lundwall	et	al	2μg	-15	
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Theti	et	al	-15	
Kumar	et	al	-17	
Overall	effect	size	
Favours	placebo																			Favours	treatment	
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5 GENERAL DISCUSSION 
In the SOLID study we show that 2 µg of paricalcitol to patients with moderate CKD 
preserves macro- and microvascular endothelial function measured by FMD and 
iontophoresis by acetylcholine, and seems to improve microcirculatory measures, in line with 
previous findings (44, 82, 111-113). We also show that this population, with few previous 
cardiovascular events, has a rapid decline in endothelial and microcirculatory functions. 
Further investigations in our patients demonstrate that treatment with paricalcitol improves 
the inflammatory profile, measured by cytokine release, also in line with previous findings in 
small RCT:s (96-99). The effects were most pronounced for the vascular inflammatory 
cytokines VEGF and PDGF showing again the positive effects of vitamin D on vascular cells. 
The upstream regulation, measured by the change in microRNAs, was also changed by 
treatment, showing lower expression of microRNAs with a connection to atherosclerosis, 
platelet function and inflammation (167, 168, 170-172). These results, however in a new 
field, give an indication of the possible upstream epigenetic effects of vitamin D on our 
laboratory and physiological findings.  
To further explore the vascular function in our patients, as well as investigate new possible 
biomarkers of cardiovascular disease, we assessed the microparticle profile pre- and post- 
treatment, as well as their expression of vascular activation markers. To our knowledge, no 
studies have previously investigated the effects of vitamin D on the MP profile in CKD 
patients. Our results on the microparticle expression on ICAM-1, showing lower expression 
with treatment, are in line with previous findings (44, 133) on soluble ICAM-1. The 
assessment of cell-specific MPs shows interesting and intriguing results, with decreasing 
production of MPs over time in all cells, however preserved by 2 µg of treatment, much like 
our physiological vascular results of FMD and iontophoresis. These findings are new and 
demand further research, but might indicate that a dysfunctional vasculature with surrounding 
cells does not have the ability to produce as much MPs, as healthy cells have. This 
interpretation is strengthened by a study of Augustine et al (158), showing lower MP levels 
after a dobutamine stress echocardiography in patients with signs of coronary disease, than in 
patients with a normal examination. 
Treatment with vitamin D in CKD patients seems to lower albuminuria on top of RAAS-
blockade (72-75), but the effects on vascular measurements are inconclusive. Most studies on 
inflammatory markers, iontophoresis and FMD have shown effect of treatment (44, 82, 111-
113, 133) but as outlined in the background, most studies using PWV/PWA have failed to 
show significant changes by treatment. The reasons for this discrepancy in findings might be 
many, but one important issue may be in the methods of measuring vascular function. 
PWV/PWA are complex measures of both arterial stiffening and calcification (PWV/PWAix) 
(12), and beta-2 induced vasodilation (PWA after administration of beta 2-adrenoceptor 
stimulation) (109), whereas FMD is primarily a measure of the capacity of the endothelial 
cells to produce and react to NO (106). As such, FMD is mainly a measure of function, not 
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structure, and is therefore probably an earlier sign of vascular disease, than PWV/PWAix. It 
is therefore likely easier to affect FMD in short duration studies, since it does not require 
structural changes to occur. Another important aspect in understanding these results are the 
cellular effects of vitamin D, with antioxidative, eNOS-upregulating actions, seen in in vitro-
studies (44, 83, 85). These are direct pathways for an ameliorated NO-production by the 
endothelial cells. Even though PWV and FMD are clearly different measures of vascular 
structure and function, they are interrelated (107, 126) and are both independent predictors of 
cardiovascular risk (17, 45, 46, 109, 126). 
In our last study, we aimed to further understand the diverging results of interventions with 
vitamin D on vascular function. As all studies performed have been quite small, they all have 
limited statistical power. We consequently performed a meta-analysis assessing the effect of 
vitamin D compounds in patients with CKD, and in accordance with the pathways for 
vitamin D actions, and the short duration of studies, we used FMD as single outcome.  Our 
meta-analysis showed that vitamin D does affect endothelial function in terms of NO 
production in a positive direction.  
The meta-analysis also gives interesting clues to which patients that might benefit the most 
from Vitamin D treatment. While all patients were in CKD stage 3 to 4, four studies had 
populations originating from western countries with a mean age of 63.9 years, while the study 
with the strongest effect size had a population originating from India, with a mean age of 44.2 
years (111). It is plausible that the structural vascular changes were not as pronounced when 
entering the study for these latter patients. Kumar et al also used cholecalciferol, raising 
questions about the potentially negative effects on calcium- and phosphate metabolism by 
active vitamin D treatment. Of interest is the sub-study by Zoccali et al (182), on the PENNY 
trial (113), showing that the effect of paricalcitol on FMD was most pronounced in patients 
with the lowest rise in phosphate, and abolished in those with the highest rise. 
Interventional studies on CKD patients have suffered from inconclusive and negative 
outcomes in many fields of research. Chronic kidney disease comprises a wide spectrum of 
underlying disorders, from hypertension, to autoimmune diseases, vasculitis, infections, 
diabetes type 1 and 2, and the inherited polycystic disease. The CKD diagnosis also includes 
patients with an almost normal kidney function, through the whole range of renal 
dysfunction, to dialysis patients with a very complex picture of disturbances due to both their 
kidney failure and the dialysis per se. When interpreting interventional studies on this group 
of patients, both the underlying disorder and the stage of kidney disease has to be taken into 
cautious consideration. In the field of vascular disease, questions have been raised if it is even 
possible to reverse or ameliorate the advanced vascular disease seen in later stages of chronic 
kidney disease (12, 13). 
The studies performed with vitamin D treatment in CKD patients are too small and of too 
short duration to answer questions on hard endpoints. PWV/PWA and FMD are both 
predictors of cardiovascular risk, whereas other measures of vascular function, such as 
iontophoresis and SEVR are less validated (126). Our meta-analysis shows that there are still 
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very few patients included in controlled studies investigating these more validated measures 
of vascular risk. There were no found studies assessing hard endpoints as an á priori outcome 
in our search.  
5.1 LIMITATIONS 
The major limitations in our RCT are the small number of participants and short duration of 
intervention. The power calculation was made for a significant change in MSNA, and not for 
FMD, and therefore we may have a lack of power in the study and a risk of type-2 errors. 
From this aspect, it might have been wiser to use only a two-group scheme, comparing 
placebo to treatment, however at the time of the study design it was not known which dose to 
use. The use of a predictor instead of hard endpoints is another limitation, however closely 
linked to the short duration, which makes hard endpoints impossible to use.  
The meta-analysis has similar limitations with each included study being small and of short 
duration, and in addition there are few studies performed. It makes the generalizability of our 
findings limited, but also highlights the need for properly sized studies in the field. 
 
6 CONCLUSIONS 
Treatment with vitamin D improves inflammation and preserves measures of endothelial 
function in patients with CKD stage 3-4. Early intervention, before manifest structural 
vascular changes have occurred, is probably needed for adequate effects. The question 
whether to use active treatment or supplementation remains, but some results are in favour of 
supplementation. Another remaining question is of other aspects of CKD-MBD, where 
studies indicate that combination therapies, controlling different aspects of the CKD-MBD 
axis, might be the right way forward. The study lengths are too short and the number of study 
participants is still too few to answer questions on hard endpoints in this field. However, the 
lack of evidence on hard endpoints due to these facts, is not to be confused with no evidence, 
and hopefully the future will give us conclusive answers. 
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7 FUTURE PERSPECTIVES 
We show effects of vitamin D treatment in CKD patients on vascular function and 
inflammation, but the results in this area are not conclusive, like in many of the research areas 
of intervention in kidney diseases. In the field of vitamin D and CKD, many questions remain 
a decade after the pleiotropic effects of vitamin D were first acknowledged.  
There are important issues of research methodology in this area. Underlying disease and 
CKD stage have to be taken into a more appropriate consideration when designing studies. Is 
it feasible to believe that we can change the late and advanced vascular disease seen in CKD 
stage 5 and dialysis patients? Would it not be better to lose some of the generalizability in the 
very broad spectrum of CKD, and instead perform studies on more specified underlying 
conditions?  
Relevant research questions have to be asked and appropriate methods used pertaining to the 
examined population and the study length. If it is not possible to use hard endpoints, which 
predictors should be used, and in which populations? Are the outcomes used good enough to 
answer our questions?  
How can we perform larger and longer studies in this area? Here, the usage of already 
existing registries, registry RCT:s is an interesting field, which gives the possibility to 
perform larger and longer studies that cost less money and without the need of industry 
involvement. Here, the Swedish Renal Registry and the SWEDEHEART registry might be of 
use.  
There are also remaining questions regarding the different aspects of CKD-MBD. This axis is 
brilliantly designed by nature to control itself, and maybe our attempts to correct one side of 
the axis are too imprecise, tipping the other side over. We need more thorough analyses of 
our results, to understand why some patients respond to treatment, and some do not. This was 
elegantly performed by Zoccali et al (182), showing that the effect of paricalcitol on FMD 
was clearly correlated to the individual rise in phosphate levels in the examined patients. Can 
we predict which patients that might respond and who will not? Can we from early stages 
combine treatments affecting the axis to better balance the effects? Here, we have to widen 
our views and cooperate in the different research fields of CKD-MBD.  
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8 SVENSK POPULÄRVETENSKAPLIG 
SAMMANFATTNING 
Nedsatt njurfunktion är en av våra vanligaste folksjukdomar och drabbar 10-15 % av världens 
befolkning. Hjärt-kärlsjukdomar är en annan stor folksjukdom, och är dessutom orsaken till 
flest dödsfall i världen. De senaste årtiondena har det alltmer uppmärksammats att patienter 
med njursvikt också i hög utsträckning drabbas av hjärtkärlsjukdom. Det är faktiskt så att de 
flesta patienter med njursvikt inte dör av sin njursvikt, utan av hjärtkärlsjukdomar som 
hjärtinfarkt eller stroke. Orsakerna har utforskats och vi har nu en god förståelse av hur 
njursvikt ger en avancerad och snabbt progredierande kärlsjukdom, med stela, kalkinlagrade 
blodkärl. Startpunkten är sannolikt en kombination av förändringar i kärlen på grund den 
minskande njurfunktionen med störningar i vitamin D, kalk och fosfatmetabolismen, 
aktivering av immunförsvaret med påföljande kronisk inflammation, och dysfunktion i det 
innersta kärllagret, endotelet. 
I detta doktorandprojekt har vårt mål varit att få en bättre förståelse för kopplingen mellan 
njursvikt och hjärtkärlsjukdom, med fokus på vitamin D-brist, kärldysfunktion och 
inflammation. 
Vitamin D genomgår sitt slutliga aktiverande steg i njuren, vilket medför att njursvikt leder 
till låga nivåer av aktivt vitamin D. Vitamin D är klassiskt känt som en viktig del i 
kalciumomsättningen, då det behövs för upptaget av kalcium. Dock har studier de senaste 
årtiondena visat att vitamin D har betydligt fler funktioner än så. Dess receptor finns spridd i 
hela kroppen, och aktiveringen sker inte bara i njuren, utan även i andra celler, bland annat 
immunceller. Vitamin D har en viktig funktion i just immunförsvaret, där det både förbättrar 
försvaret mot bakterier, men också verkar antiinflammatoriskt, och minskar nivåerna av 
oxidanter i kroppen.  
Det inre kärllagret, endotelet, har en mycket viktig funktion i kärlen då det styr kärlens 
sammandragning vilket i sin tur påverkar blodtrycket. Endotelet aktiverar och styr också 
immunceller och blodplättar, och endoteldysfunktion är en av de tidiga hörnstenarna i 
åderförkalkning, ateroskleros. Endoteldysfunktion har därför också visat sig korrelera till risk 
för framtida hjärtkärlhändelser. En viktig del i endoteldysfunktion är inflammation orsakat av 
aktiverade immunceller samt höga nivåer av oxidanter, bildade både från aktiverade 
immunceller och från endotelet självt. Vitamin D är därför intressant som en möjlig väg att 
påverka njursviktspatienters förhöjda risk för hjärt-kärlsjukdom, genom att verka 
antiinflammatorisk och antioxidativt på blodkärlens endotel. 
Vi har därför utfört en randomiserad dubbelblind placebokontrollerad studie, på 36 
njursviktspatienter utan diabetes, med njursvikt stadium 3-4. De lottades till placebo, eller 
behandling med 1 eller 2 µg paricalcitol, en aktiv vitamin D-analog. Vi undersökte 
kärlfunktionsmått, inflammatoriska parametrar, samt epigenetisk påverkan. Vi undersökte 
också en möjlig ny biomarkör för kärlfunktion, mikropartiklar, före och efter behandling. 
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Våra patienter var i genomsnitt 65 år gamla, och hade en måttligt nedsatt njurfunktion (medel 
estimerad njurfunktion GFR 40ml/min). De hade få tidigare hjärtkärlhändelser.  
I studie I visade vi att behandling med 2 µg paricalcitol ledde till en bevarad endotelfunktion, 
medan denna försämrades i placebogruppen, och gruppen som behandlades med 1 µg 
paricalcitol. Mikrocirkulationen förbättrades för båda behandlingsgrupperna, men 
försämrades för placebogruppen. 
I studie II undersökte vi inflammationsprofilen mätt i form av cytokiner, före och efter 
behandling. Här såg vi en minskad inflammation av både 1 och 2 µg behandling, dock 
tydligast visat med minskande nivåer av VEGF och PDGF, två cytokiner direkt kopplade till 
kärlfunktion och ateroskleros. Här undersöktes också epigenetisk påverkan i form av 
microRNA, som styr vilka mRNA som kommer att aktiveras och därmed bilda proteiner. Vi 
visar lägre nivåer av tre microRNA, kopplade till ateroskleros, blodplättsfunktion, och 
inflammation. 
I studie III undersökte vi mikropartiklar, som produceras från celler när dessa är stressade, 
aktiverade eller döende. Nivåer av endotelmikropartiklar har därför kunnat korreleras till 
endotelfunktion och även risk för hjärtkärlhändelser. Vi undersökte även 
mikropartikeluttrycket av ICAM-1 och VCAM-1, vilka är kärldysfunktionsmarkörer. Vi 
visade att behandling med 1 och 2 µg paricalcitol ledde till minskade nivåer av uttrycket av 
ICAM-1, medan värdena steg i placebogruppen. Mikropartikelnivåerna sjönk för patienter i 
placebogruppen och 1 µg-gruppen, men var bevarade för gruppen behandlad med 2 µg. Vi 
tolkar dessa fynd som ett tecken på att behandling bevarar kärlfunktion och minskar celldöd. 
Studie IV var en meta-analys av alla genomförda behandlingsstudier med vitamin D till 
njursviktspatienter, där utfallet var endotelfunktion mätt med flödesmedierad vasodilatation. 
Vi hittade fyra publicerade studier, med sammanlagt 305 deltagare. Den sammanlagda 
effekten av behandling med vitamin D visade på en förbättrad endotelfunktion vid 
behandling. Vår meta-analys ger också indicier på att det kan vara bättre att behandla från 
yngre ålder, och tidigare i förloppet av njursvikt. 
Detta doktorandprojekt visar att vitamin D har positiva effekter på kärlfunktion och 
inflammation. Vi behöver dock mer forskning för att kunna välja rätt patienter att behandla 
och vi bör sannolikt starta behandlingen tidigt, innan kärlsjukdomen hunnit bli alltför uttalad. 
Vi behöver också förstå hela aterosklerosprocessen vid njursvikt bättre, då det sannolikt krävs 
behandlingar från flera håll och samarbete inom forskningsfältet för att bättre balansera 
systemet och minska dessa patienters aggressiva kärlsjukdom. 
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